Conmed raises FY23 EPS view $3.40-$3.55 from $3.30-$3.50, consensus $3.42

Based on the second quarter results, the Company is raising its revenue guidance for the full year 2023 and now expects revenue between $1.230 billion and $1.260 billion, compared to its prior guidance of between $1.205 billion and $1.250 billion, FY23 revenue consensus $1.23B. The Company now expects full-year 2023 adjusted diluted net earnings per share in the range of $3.40 to $3.55, compared to its prior range of $3.30 to $3.50. The expected impact of foreign currency exchange rates is unchanged from the Company’s prior guidance.